GEMMA Biotherapeutics, co-founded by Jim Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine, announced that its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil by ANVISA, the Brazilian health regulatory agency. Read more here.